Cipla Ltd.Record Q1 Revenue, Banking on 4 Major U.S. Launches

Cipla delivered a record Q1 FY27 revenue of ₹7,100 crore, up 2% year-on-year (4% adjusted), driven by exceptional India performance which achieved its highest-ever quarterly revenue with 12% growth.

The India branded prescription business delivered market-leading 15.4% growth with chronic therapies now comprising 60.4% of the portfolio mix, led by diabetes growing at 43% and cardiac at 20%. EBITDA margin compressed to 16.7%, impacted by war-related costs, pre-launch expenses, and product mix headwinds. Management characterized this as a transitional phase with sequential improvement expected from Q3 onwards. The company successfully launched generic Ventolin in the U.S. with six-month exclusivity and holds 21% market share in albuterol MDI.

Cipla's ambitious guidance targets 18.5-20% EBITDA margins for FY27 and a $1 billion quarterly U.S. exit rate, contingent on four critical pending approvals: three respiratory assets including generic Advair and one key peptide product. Profit after tax stood at ₹789 crore (11% of sales) with a strong net cash position of ₹9,494 crore after dividend payout.